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BACKGROUND. The purpose of the current study was to determine the prevalence
of low bone mineral density (BMD) (ie, osteopenia) and identify factors asso-
ciated with low BMD in young adult survivors of childhood acute lymphoblastic
leukemia (ALL).
METHODS. Dual energy x-ray absorptiometry was used to evaluate BMD in 74
randomly selected, long-term childhood ALL survivors initially treated in Minnea-
polis/St. Paul, Minnesota. Growth hormone (GH)-releasing hormone–arginine sti-
mulation testing was conducted to evaluate peak GH level, and insulin-like
growth factor I (IGF-I) and other markers of endocrine functioning were also
evaluated in relation to BMD.
RESULTS. The mean age at the time of interview was 30 years, and the mean
time since diagnosis was 24 years. Low BMD (Z-score, 21) was present in 24%
of subjects, including 1 with osteoporosis. Low BMD was substantially more pre-
valent in men than in women and was strongly associated with short height. The
mean height Z-score for those with low BMD was 21.44, compared with a height
Z-score of 20.39 (P < .01) for those with normal BMD. GH insufficiency, low IGF-
I Z-score, and current smoking were also suggestive risk factors for low BMD.
CONCLUSIONS. In this long-term follow-up study of childhood ALL survivors, low
BMD was found to be more prevalent than expected based on population nor-
mative data, specifically in men. The health consequences of early-onset BMD
problems in childhood ALL survivors need to be carefully monitored. Cancer
2008;113:3248–56.  2008 American Cancer Society.
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T here are many known risk factors for low bone mineral density(BMD) and its associated morbidity in adults. These include
advancing age, sedentary lifestyle, low calcium intake, vitamin D
deficiency, hyperparathyroidism, smoking, white or Asian race, and
onset of menopause.1 Childhood acute lymphoblastic leukemia
(ALL), the most common pediatric malignancy,2 is also a potential
risk factor for low BMD among adults who survive their disease and
its treatment.3-7 The ALL disease process may alter bone mineraliza-
tion, as evidenced by a high proportion of children with ALL found
to have low 1,25(OH)2D3 and osteocalcin levels or hypercalciuria at
diagnosis.4,8 In addition, high-dose glucocorticoids and intrathecal
methotrexate, included in nearly all ALL treatment regimens, can
affect bone formation, at least temporarily, by altering osteoblastic
activity and proliferation.3,7,9-13 Many current adult survivors of ALL
were treated with cranial radiation, which also affects bone growth
and repair. Radiation-associated damage to the hypothalamic-pitui-
tary axis can result in growth hormone (GH) deficiency and hypogo-
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nadotropic/hypergonadotropic hypogonadism.5,14-19
Long-term endocrine abnormalities affect bone
growth during childhood and the process of bone
turnover and repair necessary for bone maintenance
during adult life. Finally, the suboptimal activity and
nutrition that these children face during their 2-year
to 3-year treatment course are likely to reduce opti-
mal bone formation during developmentally critical
time periods.12,20
The possibility that adult GH status among survi-
vors of childhood ALL may be important to long-
term bone health is of particular interest. Both GH
and its byproduct, insulin-like growth factor I (IGF-
I), are important regulators of the longitudinal
growth of bone, and the process by which adult bone
is maintained.21,22 GH and IGF-I appear to directly
stimulate the proliferation and function of osteo-
blasts and chondrocytes.22 Chen et al performed
hypophysectomies in rats and, even after replacing
thyroid and glucocorticoid hormones, found
decreased bone volume, trabecular number, and tra-
becular thickness.23 In another study, the same group
of authors added GH to the replacement regimen af-
ter the hypophysectomies, preventing loss in cortical
and cancellous bone.24
Low BMD is prevalent in individuals with either
childhood-onset or adult-onset GH deficiency
(GHD), and is particularly problematic for those indi-
viduals whose GHD onset occurred when they were
children.25,26 Replacement during childhood does not
completely alleviate the problem. Even children with
GHD who were treated optimally with GH until they
reached final adult height had BMD values 0.5 stand-
ard deviations (SD) below age-matched means as
adults.27 This may be because bone mass continues
to accrue until the late 20s or early 30s.22 Although
to our knowledge the impact of low BMD during
early adulthood on long-term morbidity is not yet
known, it appears possible that an early uncompen-
sated BMD deficit may increase an individual’s risk
for early fracture,27 long before it is expected with
natural aging.
In a previous evaluation completed by our group,
we reported that 64% of young adult survivors of
childhood ALL had either insufficient or deficient
responses to GH stimulation testing.28 Because we
also measured BMD in these individuals, and
because our participants had a mean age of 30
years-the age range at which accrual of bone mass is
believed to cease-we had a unique opportunity to
also examine the association between GHD and
BMD in this cohort. The primary objective of this
analysis was to determine the prevalence of reduced
BMD in young adult survivors of childhood ALL. The
second aim was to establish whether BMD deficits
were associated with ALL treatment factors, includ-
ing cranial radiation, or treatment-related factors
such as GH deficiency or insufficiency. Because IGF-I
is important in bone formation and repair, we also
examined whether reduced IGF-I levels were asso-
ciated with lower BMD.
MATERIALS AND METHODS
As described in greater detail previously,28 we
recruited 75 active participants from the Childhood
Cancer Survivor Study29 who were treated for ALL at
either the University of Minnesota Children’s Hospi-
tal or Children’s Hospitals and Clinics of Minneapo-
lis/St. Paul, Minnesota and diagnosed before age 21
years. From 207 eligible ALL survivors, potential sub-
jects were stratified by past cranial radiation treat-
ment (no cranial radiation, <24 grays [Gy], and 24
Gy), and 25 subjects from each treatment group were
recruited using a block randomization sampling
scheme designed to minimize the potential for favor-
ing inclusion of ‘‘fast responders.’’ Twenty-nine (14%)
subjects actively or passively refused, 22 (10.6%)
were lost to follow-up, 10 (4.8%) agreed to participate
but were never scheduled because accrual in their
block was met, and 71 (34.3%) were never contacted
because their random number was not reached in
our sampling scheme before the final recruitment
sample size of 75 was reached. Written informed
consent was obtained for each subject as approved
by the human subjects review committees at the
participating hospitals.
Biochemical tests were conducted in the fasting
state at the General Clinical Research Center at the
University of Minnesota. The GH-releasing hormone
with arginine stimulation test (GHRH/ARG) for
measuring peak GH secretion30,31 was completed for
72 of the 75 participants. GH-releasing hormone was
administered at 1 lg/kg as an intravenous bolus fol-
lowed immediately by an intravenous infusion of ar-
ginine HCL (0.5 g/kg, maximum 30 g) given over 30
minutes. GH levels were obtained at 30 minutes, 40
minutes, 60 minutes, 90 minutes, and 120 minutes
after completion of the arginine infusion. Consistent
with previous studies using the GHRH/ARG stimula-
tion test,31,32 peak GH level was categorized into 3
qualitative categories: normal GH, >16.5 lg/L; GH
insufficient, 9 to 16.5 lg/L; and GH deficient, <9 lg/
L. Insulin, IGF-I, thyroxine, and thyroid-stimulating
hormone were measured with chemiluminescent
immunoassays.33 Three subjects had missing data for
IGF-I (not the same 3 subjects with a missing GH
study). The chemiluminescent immunoassays for
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IGF-I were performed at ARUP Laboratories. Standar-
dized IGF-I Z-scores were calculated based on the
participant’s age and sex according to the method
described by Brabant34 and used by ARUP Laborato-
ries.35 This method uses a cutoff of <2 SD below the
predicted mean based on a mathematic modeling
method to define abnormally low IGF-I.34 The cutoff
values for low IGF-I using this method are consider-
ably lower than other published standards, such as
Esoterix.36
BMD was measured by dual-energy x-ray
absorptiometry (DXA) (Prodigy software [version 6.7];
GE Lunar, Madison, Wis), which provided Z-scores
standardized to sex, age, weight, and race/ethnicity
for femoral neck, lumbar spine (L2-L4), and total
body. Leukemia treatment data were abstracted from
medical records as part of the Childhood Cancer Sur-
vivor Study.29 The official position of the Interna-
tional Society for Clinical Densitometry states that
the World Health Organization classifications (T-
scores) for osteoporosis and osteopenia are not ap-
plicable to premenopausal women or to men, and
recommended instead that Z-scores be used.37
Therefore, using the lowest Z-score of the femoral
neck, lumbar region, or total body, we defined low
BMD as a Z-score 21, and osteoporosis as a Z-
score 22.5, compared with individuals of the same
sex, age, weight, and race, at 1 of the 3 measures.
Published data from the National Health and
Nutrition Examination Survey (NHANES) were used
to define age-specific and sex-specific normative
values for height in non-Hispanic white Americans38;
from these data, a height Z-score was calculated for
each study participant. The frequencies and propor-
tions of low BMD were calculated across categoric
variables and compared using the chi-square or
Fisher exact tests. Unadjusted odds ratios (ORs) and
corresponding 95% confidence intervals (95% CIs)
were estimated from logistic regression models. Dif-
ferences in continuous variables were analyzed using
the Student t test. Pearson correlation analyses were
used to estimate linear associations between vari-
ables.
RESULTS
We previously showed that there were no statistically
significant differences between the 75 subjects in the
study and the remaining cohort of 132 ALL survivors
presumed eligible to participate, according to sex,
age at time of diagnosis or interview, body mass
index (BMI), years of survival, or chemotherapies
received.28
One male subject was too large to fit in the DXA
machine and was not included in this analysis. Table
1 shows mean values, stratified by sex and low BMD
status, for clinical variables among the 74 subjects
who underwent a DXA scan. The mean age at the
time of the interview was 30 years, and the mean
time since diagnosis was 24 years. Neither time fac-
tor differed by sex. Male ALL survivors in the study
were considerably shorter on average than same-age
white men based on NHANES population norms
(mean height Z-score 5 21.06), with only a minor
difference in average height noted among female
subjects compared with female population norms
(mean Z-score 5 20.35). Male subjects also had a
lower mean peak GH level (18.5 lg/L) than did
female subjects (34.8 lg/L) (P 5 .06). Overall, 18
(24%) subjects had a BMD that was 1 SD below the
mean, including 1 whose BMD was 22.5 SD.
The mean height Z-score was the only character-
istic or biologic value that statistically differed at a
type I error probability of 5% between those with
versus those without low BMD. The mean height Z-
score was 21.44 for subjects with low BMD com-
pared with 20.39 (P < .01) for those without low
BMD. The Z-scores for BMD by femoral neck, L2-L4
lumbar spine, and total body are also shown in Table
1. Matched by sex, age, weight, and race/ethnicity,
the lowest mean BMD Z-score for those with low
BMD was in the lumbar spine (21.12), and the mean
Z-score for the lowest of the 3 site scores was 21.44.
The distribution of selected demographic and
clinical characteristics is presented in Table 2, focus-
ing on the relative proportion with low BMD. Low
BMD was present in 40% of current smokers com-
pared with 20% of nonsmokers (P 5 .17). A substan-
tially higher proportion of low BMD was observed in
men (36%) than in women (16%) (P 5 .06), and a
strong differential was noted between those with a
height Z-score of 21 (48% with low BMD) com-
pared with a height Z-score of > 21 (11% with low
BMD) (P < .001). Current smokers tended to have a
higher likelihood of a low BMD, as did subjects with
an abnormally low peak GH level or an abnormally
low IGF-I level; however, random variability could
not be ruled out as an explanation for these latter
differences. There was some indication, although not
statistically precise, that cranial radiation therapy of
24 Gy may be a risk factor for low BMD. BMI cate-
gory did not appear to be associated with prevalence
of low BMD, nor did fasting insulin level.
Because prevalence of low BMD appeared to dif-
fer substantially by sex and by height, we evaluated
the interactive effect of sex and height Z-score on
low BMD. Although men were more likely than
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women to be shorter than expected based on popu-
lation norms (21 SD for height), the odds of having
prevalent low BMD among short women compared
with nonshort women (OR, 12.50; 95% CI, 1.95-80.25)
was considerably stronger than that of short men
compared with nonshort men (OR, 4.00; 95% CI,
0.81-19.82). The male-female difference in BMD
(lowest Z-score of any site evaluated) by height Z-
score is illustrated in the 2 panels of Figure 1. For
women, a fairly strong linear correlation (r 5 0.64; R2
5 0.42 [P < .001]) between BMD and height Z-score
is observed, whereas in men the evidence for a linear
correlation was substantially weaker (r 5 0.23; R2 5
0.051 [P 5 .22]).
DISCUSSION
In this long-term follow-up study of young adult sur-
vivors of childhood ALL, we found that 24% of sub-
jects had an abnormally low BMD based on DXA
scan results. Several studies have been published
both supporting and refuting the premise that low
BMD is a significant negative outcome for childhood
ALL survivors because of their disease, treatment, or
associated effects.3,5,7,19,39,40 Arikoski et al found
decreased BMD in both the lumbar and femoral
regions among 29 survivors of ALL who had received
cranial irradiation and were tested approximately 8
years after completion of therapy.3 Brennan et al
found low BMD values among 31 adults who were
examined approximately 17.8 years after ALL diagno-
sis.39 In contrast, Kadan-Lottick et al, although they
demonstrated decreased BMD during maintenance
therapy in children treated for ALL, reported BMD
recovery in the same children shortly after comple-
tion of therapy.6 Both Van der Sluis et al and Lequin
et al also found that, even in children treated for ALL
with high-dose dexamethasone and methotrexate but
not cranial irradiation, there were no significant
long-term effects on height, BMD, or lean body mass
and fat percentage at 10 years after treatment.7,41 To
our knowledge, the current study is 1 of the larger
studies that included a long time period from diag-
nosis, and provides some support for the hypothesis
that a potential serious effect of childhood ALL and
its treatment is low BMD in early adulthood.
TABLE 1
Demographics and Study Variables by Sex and Low Bone Mineral Density Status
Total (n574) Men (n531) Women (n543)
P
Normal BMD*
(n556) Low BMD* (n518)
PMean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Age at interview, y 30.04 (7.23) 30.84 (7.39) 29.45 (7.14) .42 29.48 (7.07) 31.75 (7.65) .25
Age at diagnosis, y 5.64 (4.34) 6.05 (5.07) 5.34 (3.77) .49 5.37 (4.39) 6.47 (4.21) .35
Survival time, y 24.4 (4.84) 24.79 (4.86) 24.11 (4.87) .56 24.11 (4.75) 25.28 (5.17) .38
Height, cm 166.01 (9.06) 171.84 (7.68) 161.8 (7.57) <.01 166.77 (8.77) 163.62 (9.77) .20
Height Z-scorey 20.65 (1.22) 21.06 (1.33) 20.35 (1.04) .01 20.39 (1.13) 21.44 (1.15) <.01
Weight, kg 74.18 (17.27) 78.72 (17.60) 70.90 (16.45) .05 74.72 (16.41) 72.47 (20.13) .63
Body mass index, kg/m2 26.87 (5.85) 26.50 (5.00) 27.14 (6.43) .64 26.90 (5.80) 26.79 (6.18) .95
Percent body fat 33.22 (11.07) 26.08 (8.15) 38.36 (10.04) <.01 33.53 (10.96) 32.24 (11.67) .67
Fat mass, kg 25.12 (12.17) 21.36 (10.3) 27.82 (12.8) .02 25.42 (11.99) 24.19 (13.03) .71
Lean mass, kg 45.36 (10.60) 53.74 (9.14) 39.32 (6.81) <.01 45.4 (10.38) 45.23 (11.55) .95
Bone mass, kg 2.71 (0.57) 3.03 (0.57) 2.47 (0.45) <.01 2.79 (0.55) 2.43 (0.54) .02
Thyroxine, ng/dL 1.07 (0.17) 1.05 (0.15) 1.07 (0.18) .60 1.06 (0.18) 1.10 (0.13) .38
TSH, mU/L 2.58 (3.96) 2.08 (0.97) 2.95 (5.15) .29 2.71 (4.53) 2.18 (1.05) .42
Insulin, mU/L 8.11 (7.92) 6.68 (4.35) 9.14 (9.64) .14 8.21 (8.11) 7.78 (7.53) .84
Peak growth hormone, lg/L 28.13 (35.13) 18.53 (29.93) 34.76 (37.21) .06 31.07 (36.4) 18.79 (29.78) .21
IGF-I Z-score (ARUP) 20.75 (0.88) 20.59 (0.88) 20.88 (0.87) .17 20.66 (0.81) 21.04 (1.05) .12
IGF-I Z-score (Esoterix) 21.23 (0.76) 21.19 (0.77) 21.27 (0.76) .67 21.14 (0.74) 21.51 (0.77) .08
Bone mineral density Z-scores
Femoral neck 0.18 (1.07) 0.14 (1.26) 0.21 (0.93) .77 0.55 (0.90) 20.97 (0.70) <.01
Lumbar (L2-L4) 0.13 (1.14) 0.13 (1.38) 0.14 (0.96) .96 0.54 (0.97) 21.12 (0.60) <.01
Total body 0.34 (1.05) 0.46 (1.16) 0.25 (0.97) .41 0.65 (0.95) 20.63 (0.70) <.01
Lowest Z-score (any site) 20.25 (1.02) 20.26 (1.21) 20.24 (0.86) .96 0.14 (0.83) 21.44 (0.48) <.01
BMD indicates bone mineral density; SD, standard deviation; TSH, thyroid stimulating hormone; IGF-I, insulin-like growth factor 1.
*Low bone mineral density was defined as a Z-score 21; normal bone mineral density was defined as a Z-score of >21.
yCalculated with age-specific and sex-specific National Health and Nutrition Examination Survey norms for non-Hispanic whites.
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TABLE 2
Demographics and Clinical Characteristics in Participants With Low Bone Mineral Density
Total No.
Low BMD*
P ORy 95% CINo. (%)
Sex .06
Female 43 7 (16.3) Referent
Male 31 11 (35.5) 2.83 0.95-8.45
Age group at interview, y .53
19-29 39 8 (20.5) Referent
30-39 27 7 (25.9) 1.36 0.43-4.33
40-45 8 3 (37.5) 2.33 0.46-11.85
Year diagnosed .60
1970-1979 33 9 (27.3) 1.33 0.46-3.87
1980-1986 41 9 (22.0) Referent
Cranial radiation treatment .24
None 25 5 (20.0) Referent
<24 Gy 24 4 (16.7) 0.80 0.19-3.42
24 Gy 25 9 (36.0) 2.25 0.63-8.06
Cranial radiation treatment .09
0-23 Gy 49 9 (18.4) Referent
24 Gy 25 9 (36.0) 2.50 0.84-7.44
Current smoker .17
No 59 12 (20.3) Referent
Yes 15 6 (40.0) 2.61 0.78-8.77
Oral contraceptives (female) .39
No 27 3 (11.1) Referent
Yes 16 4 (25.0) 2.67 0.51-13.88
Height Z-score{ <.01
Z-score 21 27 13 (48.1) 7.80 2.36-25.79
Z-score >21 47 5 (10.6) Referent
Height Z-score{ .03
Z-score 22.25 6 4 (66.7) 7.71 1.28-46.50
Z-score >22.25 68 14 (20.6) Referent
Body mass index, kg/m2 .74
Normal (<25) 34 9 (26.5) Referent
Overweight (25-29.9) 18 3 (16.7) 0.56 0.13-2.38
Obese (30) 22 6 (27.3) 1.04 0.31-3.49
Peak growth hormone, lg/L .47
Normal (>16.5) 26 4 (15.4) Referent
Insufficient (9-16.5) 13 4 (30.8) 2.44 0.50-11.97
Deficient (<9) 32 9 (28.1) 2.15 0.58-8.02
Peak growth hormone, lg/L .20
Normal (>16.5) 26 4 (15.4) Referent
Low (16.5) 45 13 (28.9) 2.23 0.64-7.76
IGF-I: ARUP Laboratories reference range .17
Normal 65 15 (23.1) Referent
Low 6 3 (50.0) 3.33 0.61-18.27
IGF-I: Esoterix reference range .01
Normal 47 7 (14.9) Referent
Low 24 11 (45.8) 4.84 1.55-15.05
BMD indicates bone mineral density; OR, odds ratio; 95% CI, 95% confidence interval; Gy, grays; IGF-I, insulin-like growth factor 1.
*Low bone mineral density was defined as a Z-score 21.
yRelative odds of having low BMD.
{Calculated with age- and sex-specific National Health and Nutrition Examination Survey norms for non-Hispanic whites.
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According to the World Health Organization,
11.2% of 30-year-old men and 18.8% of 30-year-old
women have low BMD.42 Although manufacturer
norms differ across DXA machines, thus making
direct comparisons tenuous, we found an opposite
sex effect: low BMD was present in a higher percent-
age of men compared with women (36% of men and
16% of women). Low BMD more often afflicts
women than men,37,43 although the sex difference we
observed in ALL survivors has been noted pre-
viously.3,20,44,45 Male subjects in our sample were not
as heavy on average (based on BMI) as the female
subjects, but BMI did not appear to be a risk factor
for low BMD in this study. A heavier weight has argu-
ably been considered to be a protective measure
against low BMD46; however, heavy weight may
interfere with the accuracy of a DXA scan, so this
phenomenon must be viewed cautiously.47
Approximately one-third of our female survivors
were using oral contraceptives (OCPs) for birth con-
trol. Although it had been debated that the estrogen
in the OCPs is protective for bone density,48,49 the
recent decrease in doses and variety of estrogen pro-
ducts may no longer be a guarantee that they are
protective.50,51 One of our male subjects (without low
BMD) was receiving testosterone replacement ther-
apy. Although estrogen is considered the more im-
portant hormone in regulating bone mass in men,
testosterone may have some independent effects on
bone formation and resorption and provide the sub-
strate needed for aromatization to estrogen.52 Andro-
gen replacement is more difficult in men and usually
is preceded by an extensive endocrine investigation
before commencement of therapy. It is possible that
some of the men who had low BMD may have had
an unrecognized testosterone deficiency.
Although these data provided some support for
our hypothesis that chronic GH insufficiency would
be associated with low BMD (28.9% of those with a
peak GH of 16.5 lg/dL, vs 15.4% of subjects with
peak GH >16.5, had low BMD), we could not reliably
rule out the possibility that this difference occurred
because of random variability (P 5 .20). Because
some of these survivors likely developed GH defi-
ciency during childhood, it is possible they were
unable to achieve optimal bone mass, leaving them
with an inadequate skeletal mineral foundation for
adult life.53
Our finding that low BMD was associated with
lower mean IGF-I Z-score is similar to that reported
by Reed et al, who demonstrated lower IGF-I levels
in a group of adults (aged 44  12 years) who had id-
iopathic osteoporosis.54 Although IGF-I can be influ-
enced by many factors, including poor nutrition and
acute and chronic illness,55 lower IGF-I levels could
represent a problem with bone mineralization among
ALL survivors, because it directly affects the function
of osteoblasts.22
The results of the current study should be inter-
preted with consideration for potential study limita-
tions. BMD measurements from DXA are dependent
on area (length and size), but do not take into
account bone depth (volumetric density).56,57 In indi-
viduals who are very short, measurements may not
be reliable.56,57 Some have advocated calculating vol-
umetric BMD in these situations,58,59 but because
89% of the adult survivors in the current study had a
height within 2 SD of the NHANES age-specific,
race-specific, and sex-specific normative means,38 we
chose not to adjust their BMDs using bone mineral
apparent density calculations. An alternative sugges-
tion could be to use quantitative computed tomogra-
phy to further assess volume and bone geometry, but
this requires a significant increase in exposure to
ionizing radiation and is not broadly available.57
Furthermore, although the results may be in the
osteopenic or osteoporotic range, this does not
necessarily equate to bone strength.57 It is recom-
mended by the International Society for Clinical
Densitometry that the diagnosis of low BMD in
FIGURE 1. The correlation between bone mineral density (BMD) and
height by sex in (A) men and (B) women is shown.
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younger individuals should not be decided solely
on densitometric criteria, because the this cate-
gorization was designed initially to classify post-
menopausal white women and their risk for
fracture.37 Z-scores were identified to help decipher
the values for younger individuals, but the fracture
risk and clinical significance has not yet been well
determined.37
Interpreting IGF-I values in our study was diffi-
cult because of the wide variability in the normative
values set by individual laboratories. Our assay was
completed through ARUP Laboratories, whose refer-
ence values were much lower than another widely
used reference laboratory, Esoterix. On the basis of
the recommendation from Granada et al, we decided
to present our IGF-I values as standard deviations,
which allowed a more uniform interpretation of the
age-related and sex-related data.34,60 It may be help-
ful for clinicians who care for cancer survivors to test
for IGF-I levels along with their normal screening
laboratories. If IGF-I is on the lower side of normal
or frankly abnormal, it may be advisable to obtain a
baseline DXA scan to document BMD and initiate
treatment with calcium and vitamin D or other
therapies as necessary.
The data from the current study were consistent
with previous evidence suggesting that smoking may
increase risk for low BMD.61,62 In addition, our
results arguably provide some indication that cranial
radiation exposure of 24 Gy, but not lower doses,
was associated with decreased BMD (OR of 2.50 for a
BMD Z-score of 21 among those who received 24
Gy vs <24 Gy or none [95% CI, 0.84-7.44]). Although
this finding may be important to the bone health of
current adult survivors of ALL who were treated with
high doses of cranial radiation, modern ALL treat-
ment for standard-risk and low-risk ALL no longer
includes cranial irradiation63 and therefore this
potential risk factor is of limited relevance for most
children treated today for ALL.
In conclusion, we found that 24% of the partici-
pants in the current study had a BMD of 1 SD
below the mean, which is a higher percentage than
expected based on the World Health Organization’s
report.42 This could not fully be explained by their
GH status or IGF-I Z-score. Shorter women appeared
to have a higher risk of developing low BMD than
shorter men, although men overall had a substan-
tially higher prevalence of low BMD than women.
Further studies will need to be conducted to define
the etiology of low BMD and predict risk factors for
any related medical consequence for these ALL survi-
vors as they age.
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